Stock CTMX CYTOMX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
1.64 USD -1.80% Intraday chart for CytomX Therapeutics, Inc. -3.53% +5.81%
May. 28 Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25 MT
May. 09 BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
AQ
CytomX Therapeutics Announces New Employment Inducement Grants
AQ
CytomX Therapeutics : Definitive Additional Materials
PU
CytomX Therapeutics : Annual Meeting Rules of Conduct
PU
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904
AQ
CytomX Therapeutics : First Quarter Earnings Update - May 8, 2024
PU
CytomX Therapeutics: Q1 Earnings Snapshot
AQ
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
AQ
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
AQ
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
AQ
CytomX Therapeutics : 2023 Annual Report
PU
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
AQ
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
AQ
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
AQ
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
AQ
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
AQ
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
AQ
CytomX Therapeutics to Present at Upcoming March Investor Conferences
AQ
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTMX Stock
  4. News CytomX Therapeutics, Inc.
  5. Press Releases